Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a pioneer in precision medicine utilizing their Dynamo platform to target previously intractable diseases such as breast cancer and genetic disorders. With a strong financial position and multiple ongoing development programs, the company is well-positioned to drive future growth and deliver value to patients and investors alike. While clinical trials inherently carry risks, strong preliminary data and potential regulatory approvals for their lead drug candidates, as well as a relatively limited competitive landscape, make Relay Therapeutics a promising investment opportunity.

Bears say

Relay Therapeutics is a precision medicine company with a focus on developing therapies for precision oncology and genetic diseases. However, their financials do not support the potential risks associated with investing in a clinical-stage company, such as limited cash and significant operating expenses. Additionally, there is concern among key opinion leaders about the potential for growth impairment with their lead product candidate compared to competitors in the same space.

RLAY has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 11 analysts, RLAY has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.